Drug Database · Clinicians

Bemiparin

Brands (1) HiborShow all

Antithrombotic agents PH FDA category

CrCl <30: 75% treatment doseRx · Prescription drug5 PH products Kidney dosing reviewed
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals

Contraindications

  • Current or past immune heparin-induced thrombocytopenia
  • Disseminated intravascular coagulation due to heparin-induced thrombocytopenia
  • Active bleeding or bleeding disorders
  • Severe hepatic or pancreatic disease
  • Central nervous system, eye or ear surgery or injury within 2 months
  • Bacterial endocarditis
  • Lesions prone to bleed (active ulcer, hemorrhagic stroke, aneurysm, brain tumor)
  • Regional anesthesia at treatment doses
  • Hypersensitivity to heparins or pork products
renalcarematters.com, reviewed

Dosing: Adult

  • Treatment of deep vein thrombosis with or without pulmonary embolism: 115 IU anti-Xa/kg SC once daily for 7 ± 2 days (under 50 kg: 5,000 IU; 50–70 kg: 7,500 IU; 70–100 kg: 10,000 IU; 100–120 kg: 12,500 IU)
  • DVT with transient risk factors, when oral anticoagulation is contraindicated or unsuitable: 3,500 IU SC once daily, up to 3 months
renalcarematters.com, reviewed

Dosing: Altered kidney function

Bemiparin is a low-molecular-weight heparin whose anti-Xa exposure is significantly higher at creatinine clearance (CrCl) below 30 mL/min. The Spanish label needs no change at CrCl 30–80 (with clinical monitoring) and reduces the treatment dose to 75% (about 85 IU/kg once daily) below 30, with anti-Xa monitoring. It has no US FDA label.

Kidney function measure: Spanish summary of product characteristics (ficha técnica) uses creatinine clearance (CrCl, mL/min).

Show full dosing details
CrCl ≥60 mL/min
Treatment of DVT: 115 IU anti-Xa/kg SC once daily for 7 ± 2 days (weight bands 5,000 to 12,500 IU) (ficha técnica).
CrCl 30–59 mL/min
CrCl 30–80: no dose adjustment; careful clinical monitoring (ficha técnica).
CrCl 15–29 mL/min
CrCl <30: exposure rises. After weighing bleeding and thrombosis risk, use 75% of the treatment dose (about 85 IU anti-Xa/kg once daily) in acute DVT; monitor closely and consider anti-Xa about 4 hours after a dose (ficha técnica).
CrCl <15 mL/min (not on dialysis)
CrCl <30: exposure rises. After weighing bleeding and thrombosis risk, use 75% of the treatment dose (about 85 IU anti-Xa/kg once daily) in acute DVT; monitor closely and consider anti-Xa about 4 hours after a dose (ficha técnica). No data below CrCl 15; unfractionated heparin is generally preferred.
Hemodialysis (intermittent)
Not studied (no hemodialysis-circuit or treatment dose for dialysis in the ficha técnica). Avoid; unfractionated heparin is preferred, with specialist input.
Peritoneal dialysis
Not addressed; if used, as CrCl <30 with anti-Xa monitoring.
CRRT
Not addressed.
  • Dialyzable? Not stated.
  • Monitoring Platelets on day 1, every 3 to 4 days and at the end of treatment (heparin-induced thrombocytopenia). Potassium before and during treatment in at-risk patients (kidney failure, diabetes), especially beyond 7 days. Anti-Xa at CrCl <30. Neuraxial anesthesia timing (ficha técnica 4.4).
Children (kidney dosing)
eGFR ≥60
Not established in children; kidney dosing not applicable.
eGFR 30–59
Not established in children; kidney dosing not applicable.
eGFR 15–29
Not established in children; kidney dosing not applicable.
eGFR <15 (not on dialysis)
Not established in children; kidney dosing not applicable.
Hemodialysis (intermittent)
Not established in children; kidney dosing not applicable.
Peritoneal dialysis
Not established in children; kidney dosing not applicable.
CRRT
Not established in children; kidney dosing not applicable.

Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.

renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.

Source: AEMPS (Spain) product information (May 2023). This generic has no US FDA label.

Dosing: Pediatric

Approved ages
Not recommended under 18 years (ficha técnica).
Usual dose
Not established.

Kidney dosing in children: see Dosing: Altered kidney function.

renalcarematters.com, reviewed

Dosage forms

Philippines

  • Solution for injection: 2,500 IU anti-Factor Xa/0.2 mL, 3,500 IU anti-Factor Xa/0.2 mL, 5,000 IU anti-Factor Xa/0.2 mL, 7,500 IU anti-Factor Xa/0.3 mL, 10,000 IU anti-Factor Xa/0.4 mL

Registered products in the Philippines

5 products registered with the Food and Drug Administration (FDA) Philippines list Bemiparin as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

All registered products5
Philippine FDA-registered products for Bemiparin
Package insert
HiborBemiparin sodium
10,000 IU anti-Factor Xa/0.4 mL Solution for Injection (SC)0.5 mL (Net content: 0.4mL) Type I pre-filled glass syringe barrel with chlorobutyl rubber plunger, polypropylene plunger rod and 27G x 1/2" AISI Type 304 stainless steel needle and a rigid needle shield, enclosed in a plastic tray (Box of 2's)
Rx
Rovi Pharma Industrial Services, S.ASpain
STADA Philippines Inc.Trader: Laboratorios Farmaceuticos Rovi S.A
BRP-012
Oct 8, 2029
HiborBemiparin sodium
2,500IU anti-Factor Xa/0.2 mL Solution for Injection (SC)0.5mL (Net content: 0.2mL) Type I pre-filled glass syringe barrel with chlorobutyl rubber plunger, polypropylene plunger rod and 27G x 1/2 AISI Type 304 stainless steel needle and a rigid needle shield, enclosed in a plastic tray (Box of 2's)
Rx
Rovi Pharma Industrial Services, S.ASpain
STADA Philippines Inc.Trader: Laboratorios Farmaceuticos Rovi S.A
BRP-008
Oct 8, 2029
HiborBemiparin sodium
3,500 IU anti-Factor Xa/0.2 mL Solution for Injection (SC)0.5 mL (Net content: 0.2 mL) Type I pre-filled glass syringe barrel with chlorobutyl rubber plunger, polypropylene plunger rod and 27G x 1/2" AISI Type 304 stainless steel needle and a rigid needle shield, enclosed in a plastic tray (Box of 2's)
Rx
Rovi Pharma Industrial Services, S.ASpain
STADA Philippines Inc.Trader: Laboratorios Farmaceuticos Rovi S.A
BRP-009
Oct 8, 2029
HiborBemiparin sodium
5,000 IU anti-Factor Xa/0.2 mL Solution for Injection (SC)0.5 mL (Net content: 0.2 mL) Type I pre-filled glass syringe barrel with chlorobutyl rubber plunger, polypropylene plunger rod and 27G x 1/2" AISI Type 304 stainless steel needle and a rigid needle shield, enclosed in a plastic tray (Box of 2's)
Rx
Rovi Pharma Industrial Services, S.ASpain
STADA Philippines Inc.Trader: Laboratorios Farmaceuticos Rovi S.A
BRP-010
Oct 8, 2029
HiborBemiparin sodium
7,500 IU anti-Factor Xa/0.3 mL Solution for Injection (SC)0.5 mL (Net content: 0.3 mL) Type I pre-filled glass syringe barrel with chlorobutyl rubber plunger, polypropylene plunger rod and 27G x 1/2" AISI Type 304 stainless steel needle and a rigid needle shield, enclosed in a plastic tray (Box of 2's)
Rx
Rovi Pharma Industrial Services, S.ASpain
STADA Philippines Inc.Trader: Laboratorios Farmaceuticos Rovi S.A
BRP-011
Oct 8, 2029

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

Drug interactions

Drug or classSeverityEffectWhat to do
Other anticoagulants, aspirin and other antiplatelets, NSAIDs, systemic corticosteroids, dextranAvoidMore bleeding.Not recommended.
Drugs that raise potassiumAdjust or monitorHyperkalemia.Only under close supervision.
Intravenous nitroglycerinMinorMay reduce effect.Monitor.

Severity scale (renalcarematters.com): Avoid: do not combine; Adjust or monitor: change the dose or monitor closely; Minor: usually no action.

renalcarematters.com, reviewed

Adverse reactions

Common

  • Bruising and hematoma at the injection site
  • Mild transient thrombocytopenia (type I)
  • Raised transaminases

Serious

  • Major bleeding
  • Heparin-induced thrombocytopenia (type II)
  • Spinal or epidural hematoma with neuraxial anesthesia
  • Hyperkalemia (hypoaldosteronism)
  • Skin necrosis
renalcarematters.com, reviewed

Monitoring parameters

  • Platelets on day 1, every 3 to 4 days and at the end of treatment (heparin-induced thrombocytopenia). Potassium before and during treatment in at-risk patients (kidney failure, diabetes), especially beyond 7 days. Anti-Xa at CrCl <30. Neuraxial anesthesia timing (ficha técnica 4.4). Kidney
  • Platelets
  • Potassium
  • Anti-Xa at CrCl <30
renalcarematters.com, reviewed

Pharmacokinetics

Key PK parameters

BioavailabilityAbout 96% (SC)
Time to peak2 to 3 hours (prophylactic), 3 to 4 hours (treatment doses)
Half-lifeAbout 5 to 6 hours
Half-life in kidney failure (ESKD) kidneyAnti-Xa exposure significantly higher at CrCl <30 (not quantified)
Renal excretion kidneyNot stated (human)
Dialyzability kidneyNot stated
renalcarematters.com, reviewed

Formulary and pricing (Philippines)

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. Agencia Española de Medicamentos y Productos Sanitarios. Hibor 7,500 IU ficha técnica (CIMA 64165) [AEMPS (Spain) product information, May 2023; no US FDA label]. https://cima.aemps.es/cima/dochtml/ft/64165/FT_64165.html
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  3. Laboratorios Farmacéuticos ROVI, S.A. (2023). Hibor 7,500 IU anti-Xa/0.3 mL solución inyectable en jeringas precargadas (bemiparin sodium) [Ficha técnica; text revised May 2023]. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), CIMA registration 64165. https://cima.aemps.es/cima/dochtml/ft/64165/FT_64165.html

renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .